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COMMENTARY
Tissue Is the Issue in Transient Ischemic
Attack and Stroke
Most of us were taught in medical school that a tran-sient ischemic attack (TIA) was a stroke syndrome
that resolved within 24 hours. With the advent of
diffusion-weighted magnetic resonance imaging (DW-
MRI), several observers noted that although clinical
symptoms had resolved in TIA patients, some had posi-
tive DW-MRI signal, implying infarcted brain.1 Because
the overwhelming majority of TIAs resolve within 1
hour, and so many patients with symptoms lasting longer
than several minutes have positive DW-MRI signal, a
new definition of TIA was proposed a decade ago, which
included brief focal neurologic symptoms referable to a
vascular territory that did not have imaging signal imply-
ing infarction.2 Conversely, a new “tissue” definition of
stroke, to distinguish it from TIA, has emerged to
encompass clinical symptoms lasting >24 hours and/or
evidence of infarcted brain at any time point, most fre-
quently observed by DW-MRI.3
At the same time that we were wrestling with the
question of when TIA ends and stroke begins, researchers
were noting that patients with TIA had very high risk of
having another event, this time a completed clinical
stroke, within the first few days to a month after a clini-
cal TIA.4 Important clinical tools to address subsequent
stroke risk in patients presenting with clinical TIA were
developed and promulgated.5 DW-MRI–positive signal is
associated with a significant increase in the risk of subse-
quent short-term stroke risk.6 Most of the studies that
have examined DW-MRI signal in clinical TIA were
designed to investigate the predictive value of DW-MRI
for short-term clinical stroke risk.
In the January issue of Annals of Neurology, Brazzelli
et al performed a meta-analysis of these studies and point
out the remarkable heterogeneity in the prevalence of
DW-MRI signal in patients presenting with brief cerebro-
vascular symptoms.7 Whenever large variability is seen in
the application of a test, in this case DW-MRI, one needs
to question the utility of the test and what accounts for
the variability. As the authors point out, even the notion
that positive DW-MRI signal is permanent and synony-
mous with infarction has been questioned.8 The authors
are correct to ponder the tremendous variability seen in
the proportion of patients presenting with brief cerebro-
vascular symptoms and positive DW-MRI. We wonder,
however, if some of this variability was introduced due to
the papers available for their analysis being focused on a
different question (Does positive DW-MRI predict short-
term stroke risk?), rather than the question of the meta-
analysis (What is the frequency of positive DW-MRI in
patients with brief cerebrovascular symptoms?). That is,
the studies included were not designed to accurately esti-
mate DW-MRI–positive prevalence among the source
population. Most meta-analyses aggregate data from
observational studies or clinical trials performed to answer
the same question.9 Perhaps the only ideal way to study
this would be to include all patients presenting with TIA
symptoms from a community or a national randomly cho-
sen sample and perform DW-MRI on all patients.
However, the meta-analysis included some studies with
consecutive patients and some community studies, and
these still showed great variability.
Brazzelli et al’s current, well-executed meta-analysis
has synthesized the available information on DW-MRI
prevalence. So what should we take away from it? It is true
that in these particular studies, there is large heterogeneity
in DW-MRI signal in clinical TIA. Recent publications
suggesting that we use MRI to operationalize a tissue defi-
nition of TIA (absence of DW-MRI signal) and stroke
(presence of DW-MRI signal) should consider and further
investigate this heterogeneity before adopting new defini-
tions for these conditions, which have been consistently
defined for decades. Certainly, epidemiologic and clinical
studies as well as national and international statistics that
guide spending for research and care would be made more
difficult if MRI is required in addition to clinical diagno-
ses. This may result in underestimation of stroke in popu-
lations without resources for MRI, such as developing
countries. In brief, the current work says, not so fast, what
does DW-MRI signal in clinical TIA really mean?
What the article does not alter is the evidence
showing a clear link between positive DW-MRI signal
among patients with brief cerebrovascular symptoms and
the very high short term risk for ischemic stroke.5,6 In
association with the rest of the ABCD2 risk algorithm,
this information should lead to urgent evaluation and
treatment of patients with very high short-term stroke
risk. This includes rapid identification of patients with
high-grade carotid artery disease and cardiac sources of
emboli. Furthermore, the recent CHANCE trial results
from China suggest the potential beneficial impact of
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clopidogrel loading combined with aspirin immediately
after TIA to prevent stroke.10 The POINT trial, which is
similar despite some important distinctions, including
the more diverse patient population, is ongoing and will
add to the CHANCE results.11
Brazzelli et al do an excellent job of making us pause
to think about what this adolescent technology, DW-MRI,
really means to the epidemiology of stroke and TIA. In a
time when technology development has outpaced our abil-
ity to know when to apply technology advancements and
when not to use new technology, we say bravo to them for
reminding us that we should think before we leap.
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